Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the efficacy of the combination of gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in patients with metastatic pancreatic cancer.

Official Title
-----------------
A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

Conditions
-----------------
Metastatic Pancreatic Cancer

Intervention / Treatment
-----------------
* Drug: Gemcitabine+erlotinib
* Drug: Gemcitabine+erlotinib+capecitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to understand and willingness to sign a written informed consent Able, in the investigator's opinion, to fulfill the procedures and explorations of the study Age ≥ 18 years old ECOG 0-2 Life expectancy ≥ 12 weeks Patients with metastatic adenocarcinoma of the pancreas, following 7th edition of TNM classification Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas Measurable disease following RECIST criteria version 1.1 No previous systemic treatment for metastatic pancreatic cancer Adjuvant chemotherapy al least 6 months before enrollment is allowed. Patients having neoadjuvant chemotherapy must have completed the treatment at least 4 weeks before trial entry. Toxicities associated to previous treatment must be resolved before enrollment. Progression disease (metastatic disease) must be confirmed after adjuvant treatment Adequate bone marrow function as determined by: Hemoglobin: ≥ 9 g/dL. (patients with hemoglobin < 9 g/dL could be transfused before their inclusion on the study) Platelets: ≥ 100 x 109/L Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L Adequate liver function, as determined by: Serum bilirubin ≤ 1,5 x LSN AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver metastasis ≤ 5 x LSN Alkaline phosphatase ≤ 2,5 x LSN or ≤ 5 x LSN in patients with liver metastasis. In patients with bone metastasis ≤ 10 x LSN Adequate renal function, as determined by: Creatinine clearance using the Cockcroft-Gault formula ≥ 50.0 ml/min Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to randomization. Postmenopausal women are defined as those who have been amenorrheic for at least 12 months. Also, both men and women enrolled in this study must use adequate birth control (eg., abstinence, intrauterine device, oral contraceptive or double barrier method or be surgically sterile), starting at the signing of the informed consent and up to at least 6 months after completion of treatment or the last dose, whichever occurs first Patients must not have undergone a major surgical procedure within 4 weeks prior to study treatment. The surgical wound should be completely healed Exclusion Criteria: Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III), following the TNM 7th edition classification. Patients with metastatic disease that relapse after the initial diagnosis of local or advance disease could be included in this study Pancreatic endocrine tumor and ampulloma Evidence of carcinomatosis meningitis or brain metastasis. In case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior de inclusion. Primary tumors developed 5 years previous to the inclusion, except in situ cervix carcinoma or skin basocellular cancer properly treated Cardiovascular disease clinically significant (active): Non-controlled arterial hypertension (Systolic pressure > 150 mg Hg and/or diastolic pressure > 100 mm Hg on repeated pressure measurements) Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion) Myocardial infarction (≤ 6 months prior to inclusion) Unstable angina Congestive cardiac insufficiency (grade II or superior following to New York Heart Association (NYHA) Severe cardiac arrythmia requiring treatment Significant ophthalmologic anomalies Deficit in Dihydropyrimidine-Dehydrogenase (DPD) Unable to take oral drug. Previous surgical process that affect the absorption or make the needed to have intravenous feeding or parenteral nutrition with lipids Pregnancy women or in lactation period Antineoplastic treatment (chemotherapy, hormonal treatment, radiotherapy, surgery, biological therapy or tumor embolization) 4 weeks prior the inclusion Previous treatment with capecitabine or EGFR inhibitor Metabolic disease or any other disease which, in the investigator's opinion, might interfere with the treatment in study Known hypersensibility to any study drug (gemcitabine, erlotinib, capecitabine) or to 5-fluorouracile and fluoropyrimidines Current infection grade ≥ 2 (CTCAE) Known human immunodeficiency virus infection, or chronic infection with hepatitis B or C virus, or severe uncontrolled intercurrent infection or other severe uncontrolled concomitant diseases Medical, psychological, psychiatric or sociological conditions that would interfere to the patient participation in the study or in the assessment of the results Current or 30 days previous to study treatment with other investigational drug or participation in other trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br>Gemcitabine+erlotinib | Drug: Gemcitabine+erlotinib<br>* Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .<br>|
| Experimental: Experimental<br>Gemcitabine+erlotinib+capecitabine | Drug: Gemcitabine+erlotinib+capecitabine<br>* Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival |  | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 4 years | 
| Response rate (RR) |  | 4 years | 
| Duration of response |  | 4 years | 
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability |  | 4 years | 
| Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatic cancer, gemcitabine, erlotinib, capecitabine